* Relay Therapeutics Inc RLAY.OQ reported a quarterly
adjusted
loss of 69 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -81 cents. The mean expectation of
twelve analysts for the quarter was for a loss of 73 cents per
share. Wall Street expected results to range from -77 cents
to -71 cents per share.
* Reported revenue was zero; analysts expected $80.00
thousand.
* Relay Therapeutics Inc's reported EPS for the quarter was
a loss
of 69 cents.
* The company reported a quarterly loss of $92.21 million.
* Relay Therapeutics Inc shares had risen by 8.9% this
quarter and
lost 35.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Relay
Therapeutics Inc is $21.00
This summary was machine generated from LSEG data August 6 at
10:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.73 -0.69 Beat
Mar. 31 2024 -0.70 -0.62 Beat
Dec. 31 2023 -0.73 -0.67 Beat
Sep. 30 2023 -0.83 -0.54 Beat